ClinicalTrials.gg
RecruitingNCT07437391Updated Feb 27, 2026

Effect of L-Carnitine Supplementation in Preterm Neonates

An interventional study of L-carnitine and Standard care in Respiratory Distress Syndrome, sponsored by Muhammad Aamir Latif. Recruiting at 1 site in Pakistan. Open to participants aged 1 Hour to 24 Hours. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by Muhammad Aamir Latif · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
1 Hour to 24 Hours
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Respiratory Distress Syndrome with a site in Pakistan — 2 open to participants now, 2 under way, none of them phase 3. Respiratory Distress Syndrome · Pakistan.

Planned enrollment
2nd of 10
160 · median 86
Started
2026
with 1 other
No phase
8 of 12
2 open now
Registered
9th of 12
by date
Lead sponsor
2 of 12
Muhammad Aamir Latif

Among the 12 studies in Respiratory Distress Syndrome with a site in Pakistan, this one is the 2nd largest by planned enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2026, is one of 8 with no phase, and was the 9th registered.

Respiratory Distress Syndrome

1,389 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.

Browse Respiratory Distress Syndrome studies →

Open to participants now

2 of the 12 studies in Respiratory Distress Syndrome with a site in Pakistan are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Pakistan have not opened yet or have stopped. Only those recruiting at a site in Pakistan →

Who these studies take

Of the 196 Respiratory Distress Syndrome studies recruiting now, 116 (59%) set no upper age limit and 50 (26%) stop at 75 or younger; 52 take children under 18; 9 take healthy volunteers.

This study: 1 Hour to 24 Hours · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Respiratory Distress Syndrome with a site in Pakistan, or all of them as a file.
02

Study summary

The current study is planned to see the effect of L-carnitine supplementation in preterm neonates suffering from RDS among the local population, as there is no such evidence available for the local population and there are conflicting statistics regarding the discharge rate of these neonates.

Read the detailed description

Given the contradictory results (discharge rate), additional rigorously designed studies are necessary to elucidate the impact of L-carnitine supplementation on short-term neonatal outcomes, including weight gain, discharge rate, and mortality. The proposed research aims to fill this knowledge gap by systematically evaluating the clinical efficacy and safety of L-carnitine supplementation in L-carnitine-deficient neonates. The findings would provide evidence-based suggestions on whether L-carnitine is a useful, safe, and potentially beneficial adjunct in managing preterm neonates with RDS, particularly in addressing metabolic needs.

03

Conditions studied

  • Respiratory Distress Syndrome
04

Who can participate

Ages eligible
1 Hour to 24 Hours
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Preterm neonates
  • Either gender
  • With RDS
  • Admitted to the neonatal intensive care unit (NICU) within 24 hours of birth .

Exclusion criteria

Exclusion Criteria:

  • Neonates with gastrointestinal tract (GIT) anomalies
  • With confirmed or suspected sepsis at the time of enrollment
  • Neonates whose clinical condition contraindicates study participation (e.g., expected survival \<48 hours, as judged by the neonatologist).
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    L-carnitine Group

    Patients will receive L-carnitine at a therapeutic dosage of 30 mg/kg/day, in conjunction with a standard care regimen comprising a total dosage of 100 mg phospholipids/kg birth weight (4 ml/kg), divided into four quarter-dose aliquots.

    Drug: L-carnitine · Drug: Standard care

  • Experimental
    No L-carnitine Group

    Patients will get only a standard care regimen comprising a total dosage of 100 mg phospholipids/kg birth weight (4 ml/kg), divided into four quarter-dose aliquots.

    Drug: Standard care

Interventions

  • DrugCarnitineStudies of CarnitineCarnitine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients will receive L-carnitine at a therapeutic dosage of 30 mg/kg/day, in conjunction with a standard care regimen comprising a total dosage of 100 mg phospholipids/kg birth weight (4 ml/kg), divided into four quarter-dose aliquots.

  • DrugStandard care

    Patients will get a standard care regimen comprising a total dosage of 100 mg phospholipids/kg birth weight (4 ml/kg), divided into four quarter-dose aliquots.

06

What researchers measure

Primary outcomes

  1. Mortality

    If a patient will die in the hospital, it will be considered as mortality, otherwise taken as discharged alive.

    Time frame: 30 days

  2. Change in Weight

    Change in weight will be measured at discharge and compared with the baseline measure. An increase in the weight from baseline will be considered effectiveness of the treatment.

    Time frame: 30 days

07

Study locations

1 of 1 sites recruiting
  • Recep Tayyip Erdogan Hospital/Indus Hospital & Health Network
    Muzaffargarh, Punjab Province 32400, Pakistan
    Recruiting
    • Muhammad Sarfraz, FCPS · Contactdrfraz1986@gmail.com · +923336464238
    • Athar Razzaq, PCPS · Contactathar.razzaq@tih.org.pk · +923007183545
    • Muhammad Sarfraz, FCPS · Principal investigator
    • Athar Razzaq, FCPS · Principal investigator
08

References and documents

Individual participant data

Plan to share: No — Data can be shared on a reasonable request.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Jun 2026, 5 months after the start.

Of 266 non-industry interventional studies with no phase under Respiratory Distress Syndrome, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's planned 5 months is below that.

Counting every sponsor, half of 273 studies reached it within 24 months; a quarter within 12 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2026
First posted
Feb 27, 2026
StartActual
Jan 1, 2026
Primary completionEst.
Jun 30, 2026
CompletionEst.
Jun 30, 2026
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07437391
Lead sponsor
Muhammad Aamir Latif
Responsible party
Muhammad Aamir Latif (Research Consultant, RESnTEC, Institute of Research) — Sponsor-investigator
First posted
Feb 27, 2026
Start date
Jan 1, 2026
Primary completion
Jun 30, 2026 (estimated)
Completion
Jun 30, 2026 (estimated)
Last update
Feb 27, 2026

Study contacts

Muhammad Sarfraz, FCPS
Contact
drfraz1986@gmail.com
+923336464238
Athar Razzaq, FCPS
Contact
athar.razzaq@tih.org.pk
+923007183545
Muhammad Sarfraz, FCPS
principal investigator · Recep Tayyip Erdogan Hospital, Muzaffargarh
Athar Razzaq, FCPS
principal investigator · Recep Tayyip Erdogan Hospital, Muzaffargarh

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Carnitine

Start the discussion